Patients afflicted with SARS-CoV-2, Influenza A (Flu A), Influenza B (Flu B), and/or Respiratory Syncytial Virus (RSV) often exhibit similar symptoms, yet necessitate distinct approaches to management. The SARS-CoV-2, Flu A/B, and RSV qualitative test streamlines the rapid triage and patient management process, swiftly identifying various viruses in under 1 hour.
This panel enables healthcare professionals to administer pathogen-specific treatments and targeted interventions effectively. By combining these tests, healthcare facilities not only streamline costs but also address the complexities of respiratory infections directly at the point of care. This integrated approach facilitates infection control measures and enhances risk assessment, ultimately contributing to more efficient and tailored patient care.
Key Benefits:
- Detection from real-time PCR via Nasopharyngeal and/or Oropharyngeal swab
- The SARS-CoV-2 DT, Flu A/B and RSV rapid test has CE marking
- Rapid turnaround time of 53 minutes from sample entry to result
- Targets the E gene and N gene sequences for COVID-19 detection, as well as Influenza A and Influenza B and human Respiratory Syncytial Virus
- Simple and easy to use analyser with a small footprint making it suitable for use in laboratory and non-laboratory settings
- Convenient 4 step process from sample entry to results. No laboratory training required